Palatin uses its expertise in the melanocortin and natriuretic peptide fields to develop next-generation peptides and mimetics addressing unmet medical needs. View our clinical pipeline.
Vyleesi™ is the trade name for bremelanotide, a first in class melanocortin-4 receptor agonist submitted for Food and Drug Administration review and approval for the “as desired” treatment of hypoactive sexual desire disorder (“HSDD”) in premenopausal women. Learn more about Vylessi.
Treating inflammatory and autoimmune diseases using melanocortin receptor-1 peptide drug candidates. Get more information on inflammatory disease therapies we are developing.
Melanocortin-4 receptor peptide drug candidates for genetic metabolic and obesity disorders. View our approach to genetic metabolic and obesity disorders.
Natriuretic peptide synthetic mimetics for treating heart failure and related indications. Learn more about heart therapeutics using natriuretic peptide mimetics.